TL;DR
Get self-care and calm essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A study published in Nature Communications linked the gut-bacteria compound imidazole propionate, or ImP, with Alzheimer’s-related biological markers and faster cognitive decline. Mouse findings suggest a possible mechanism, but the human data are observational and do not show that ImP causes Alzheimer’s or that lowering it prevents the disease.
Researchers reported that imidazole propionate (ImP), a molecule made by some gut bacteria, was associated with Alzheimer’s-related protein changes in mice and faster cognitive decline among people with higher blood levels. The study, published in Nature Communications, points to a possible biological link and future treatment target, but it does not establish that ImP causes Alzheimer’s disease in people.
The team, led by University of Wisconsin-Madison researchers Barbara Bendlin and Federico Rey, examined ImP, a compound that certain intestinal bacteria produce while using histidine, an amino acid people need and obtain from food. ImP levels vary widely: the researchers said the bacteria that make it are present in many people but generally are not abundant. The molecule can enter the bloodstream after it is produced in the gut.
In experiments with mice, the researchers found that ImP reaching the brain increased the accumulation of abnormal beta-amyloid and tau proteins, which are associated with Alzheimer’s disease. The mouse results offer evidence of a possible mechanism, but findings in animals do not by themselves show that the same process drives disease in humans.
The researchers also analyzed blood samples from nearly 1,200 participants in the Wisconsin Registry for Alzheimer’s Prevention and studies through the Wisconsin Alzheimer’s Disease Research Center. Higher ImP concentrations were associated with biological markers of abnormal proteins and impaired neuron function, as well as faster changes in cognitive test results over time. The study report describes an association, not proof that ImP caused the participants’ decline.
The team identified a genetic variation associated with substantially higher blood ImP levels. About 43% of participants carried it. Researchers proposed that the variation could affect how effectively the kidneys clear ImP from the blood. They also noted that the genetic variation had been associated with Alzheimer’s risk in previous large genetic studies; the new research suggests one possible explanation for that connection, rather than confirming it.
A Possible Target Beyond Diet
The findings give researchers a specific molecule to investigate in the relationship between the gut and the brain. If further work confirms that ImP contributes to disease processes, a treatment that reduces its levels could offer a way to intervene in a pathway linked to Alzheimer’s risk or decline. At present, that is a research possibility, not an available prevention strategy or a proven treatment.
The researchers cautioned against treating the result as a reason to avoid particular foods. Gut bacteria produce ImP from histidine, which is essential and found in many foods, especially protein-rich foods. Bendlin said broad dietary improvement could be beneficial in general, but removing foods such as eggs or red meat would not amount to a simple way to eliminate the compound. The study did not test a diet change or show that changing food intake lowers ImP or dementia risk.
A blood marker linked to cognitive change could also help scientists investigate why risk differs among people. But the reported data do not establish how much ImP contributes compared with other genetic, health, or environmental factors, or whether an ImP-lowering intervention would affect patients’ outcomes.
As an affiliate, we earn on qualifying purchases.
From Gut Differences to ImP
The work follows nearly a decade of research by Bendlin, Rey, and colleagues into differences in gut microbes between people with Alzheimer’s disease and healthy individuals. Their earlier observations raised a question that the team has since pursued: whether differences in the intestinal microbiome can relate to changes in the brain, and through what biological routes.
ImP had already attracted research interest because previous studies linked it with type 2 diabetes and coronary artery disease. The new report extends investigation of the molecule to brain-related outcomes. Scientists from the University of California, Los Angeles, and the University of Gothenburg also contributed. The study received support from the Wisconsin Partnership Program, the National Institutes of Health, and the U.S. Department of Agriculture.
“Since then, we’ve been trying to figure out how this difference in the gut perhaps leads to changes in the brain.”
— Barbara Bendlin, University of Wisconsin-Madison professor of medicine
As an affiliate, we earn on qualifying purchases.
Cause and Treatment Still Unproven
The human results show that higher ImP levels were associated with biological markers and faster cognitive decline; they do not establish that the molecule caused either outcome. The mouse experiments support a possible mechanism but cannot settle whether it operates in the same way, or to the same degree, in people. The report does not establish whether lowering ImP would prevent Alzheimer’s, slow progression, or improve cognition.
It is also not clear from the reported findings how the genetic variation affects ImP clearance, how much kidney function explains the difference, or which people might benefit from a future intervention. The study did not demonstrate that a particular diet lowers ImP, and no ImP-targeting treatment was tested. The size of any potential effect on an individual’s risk remains uncertain.
As an affiliate, we earn on qualifying purchases.
Testing ImP-Lowering Strategies
The next step is further research to test the proposed links between ImP, its clearance from the blood, and brain changes. Researchers would need to establish whether the associations hold in additional groups and whether reducing ImP can alter relevant biological markers or cognitive outcomes. Any medicine intended to lower the molecule would also need to be tested for safety and benefit in clinical trials before it could be considered for patient care.
For now, the study identifies a candidate pathway for investigation, not a recommendation to change diet or a new Alzheimer’s treatment. The available report does not specify a timeline for an ImP-lowering drug or clinical trial.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is imidazole propionate?
Imidazole propionate (ImP) is a compound produced by certain gut bacteria as they use histidine, an amino acid essential to human health. It can enter the bloodstream after being made in the gut.
Does this study prove that ImP causes Alzheimer’s disease?
No. The mouse experiments found changes in Alzheimer’s-associated proteins, while the human data showed associations between blood ImP levels, biological markers, and cognitive decline. Those findings do not prove that ImP causes Alzheimer’s in people.
Should people avoid eggs or meat to lower ImP?
The study did not test dietary changes or show that avoiding particular foods lowers ImP. The researchers said histidine is essential and present in many foods, so the findings do not support a simple food-avoidance recommendation.
Is there a treatment that lowers ImP?
The report describes ImP as a possible future treatment target, but it does not report a tested ImP-lowering drug or show that lowering the molecule prevents or slows Alzheimer’s disease.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
